View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 20, 2021

Todos Medical starts trial of protease inhibitor to treat Covid-19

Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollovir), a potent 3CL protease inhibitor to treat hospitalised Covid-19 patients.

Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollovir), a potent 3CL protease inhibitor to treat hospitalised Covid-19 patients.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The 77-patient, randomised, double blind, placebo-controlled trial is being conducted at Shaare Zedek Medical Center in Jerusalem, Israel.

Todos Medical is developing the therapeutic agent Tollovir through a joint venture with NLC Pharma.

The company has dosed the first ten patients in the trial.

NLC Pharma co-founder and chief scientific officer Dr Dorit Arad said: “The launch of this clinical trial is a critical step towards the clinical validation of our proprietary scientific work that was recently further supported with data from the Dan Peer laboratory at Tel Aviv University in Israel, concluding that our proprietary medical grade 3CL protease inhibitor, Tollovir, is an antiviral therapeutic candidate for SARS-CoV-2’s based on its 3CL protease reproduction mechanism.

“I am glad that my pioneering academic work over the last 30 years on 3CL mechanisms has made such a significant impact, and that it is finally being recognised by leading pharmaceutical companies as a key target in the war against Covid-19 that could yield an easy-to-administer oral antiviral therapeutic capable of stopping SARS-CoV-2 replication, independent of different mutations that are emerging at the site of spike protein.”

Dose selection for the Phase II trial is supported by data from a randomised, placebo controlled, open label Phase Ib trial in 27 hospitalised patients with Covid-19.

Time to discharge from the hospital and time to clinical improvement based upon the National Early Warning Score 2 in Israel form the primary endpoints of the trial.

Secondary endpoints that are being examined are rate of change of measured parameters, rate of change in vital signs including blood pressure, heart rate, respiratory rate, saturation, and body temperature.

Time from the first day of receiving NLC-V treatment to negative RT-PCR test result, Covid-19 related deaths, incidence of deterioration, and need for mechanical ventilation and incidence and duration of time on supplemental oxygen are also being examined.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena